ClinicalTrials.gg
Not yet recruitingNCT07797608PMR-PAUpdated Sep 9, 2026

Effect of Progressive Muscle Relaxation on Parental Anxiety

An interventional study of Progressive Muscle Relaxation in Parent, Anxiety and Cancer, sponsored by Akdeniz University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-09-09.

Primary conditionNeoplasmsRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Neoplasms
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Akdeniz University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
112
Allocation
Randomized
Sex
All
01

Study summary

This randomized controlled trial aims to evaluate the effect of progressive muscle relaxation exercises on anxiety levels among parents who are the primary caregivers of children diagnosed with cancer and receiving inpatient treatment. A total of 112 parents will be randomly assigned to either the intervention or control group. Parents in the intervention group will participate in researcher-led progressive muscle relaxation sessions. Anxiety will be assessed using the State Anxiety Inventory (STAI-I). The study will be conducted at the Pediatric Hematology-Oncology Clinic of Akdeniz University Hospital in Antalya, Türkiye.

Read the detailed description

Parents of children diagnosed with cancer may experience substantial anxiety throughout their child's diagnosis and treatment. Progressive muscle relaxation is a nonpharmacological technique involving the systematic tensing and relaxing of major muscle groups combined with deep breathing. Eligible parents will be randomly allocated in equal numbers to the intervention or control group using a computer-generated randomization sequence. The intervention will be delivered individually in a private clinical education room. Participants will progressively tense and relax the muscles of the face, neck, shoulders, chest, abdomen, legs, and feet. Each muscle group will be tensed for 5 seconds and relaxed for 10 seconds while participants practice deep breathing and visualize a wave of relaxation throughout the body. Anxiety will be assessed using the State Anxiety Inventory (STAI-I), and changes in anxiety scores will be compared between the groups.

02

Conditions studied

  • Parent
  • Anxiety
  • Cancer
  • Progressive Muscle Relaxation
  • Nursing

Browse trials for

Keywords

  • Parent
  • Anxiety
  • Cancer
  • Progressive Muscle Relaxation
  • Nursing
03

In context

Neoplasms Reclassified

10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's planned enrollment of 112 is above the median of 60 across 7,703 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Akdeniz University is the lead sponsor of 297 studies on the registry; 62 are open to participants now.

Compared within Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being the parent and primary caregiver of a child diagnosed with cancer
  • The child having been diagnosed with cancer within the previous 12 months
  • The child currently receiving inpatient treatment in the study clinic
  • Being able to communicate without hearing or speech-related barriers
  • Being able to understand and answer the study questions
  • Providing written

Exclusion criteria

Exclusion Criteria:

  • Not meeting any of the inclusion criteria
  • Withdrawing consent at any time
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    Progressive Muscle Relaxation

    Participants will receive two individual progressive muscle relaxation sessions in a private clinical education room over two weeks. Each session will last approximately 15 minutes and will be conducted once weekly.

    Behavioral: Progressive Muscle Relaxation

  • No intervention
    Control

    Participants in the control group will receive routine care provided by the clinic and will not participate in progressive muscle relaxation sessions during the study period.

Interventions

  • BehavioralProgressive Muscle Relaxation

    Participants will receive routine clinical care and will not participate in progressive muscle relaxation sessions during the study period.

06

What researchers measure

Primary outcomes

  1. Change in State Anxiety

    State anxiety will be measured using the State Anxiety subscale of the State-Trait Anxiety Inventory (STAI-S). The subscale contains 20 items and yields a total score ranging from 20 to 80. Higher scores indicate higher state anxiety.

    Time frame: 2 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Jul 2027, 11 months later.

Of 1,981 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 11 months is below that.

Counting every sponsor, half of 2,056 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2026
First posted
Sep 1, 2026
StartEst.
Aug 15, 2026
Primary completionEst.
Jul 20, 2027
CompletionEst.
Jul 20, 2027
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07797608
Lead sponsor
Akdeniz University
Responsible party
Duygu ALTUNTAŞ (Lecturer, PhD, Akdeniz University) — Principal investigator
First posted
Sep 1, 2026
Start date
Aug 15, 2026 (estimated)
Primary completion
Jul 20, 2027 (estimated)
Completion
Jul 20, 2027 (estimated)
Last update
Sep 9, 2026

Study contacts

Duygu Altuntaş, PhD
principal investigator · Akdeniz University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion